

## Methodological Note 4.0

EFPIA & Local Industry Association Disclosure Codes

## 1. INTRODUCTION

Amgen is committed to transparent interactions with Healthcare Professionals (HCPs), Healthcare Organisations (HCOs) and Patient Organisations (POs). Our interactions take place through collaboration during early scientific research, clinical trials, medical and scientific education all of which are intended to advance patient care by bringing innovative medicines to patients.

HCPs, HCOs, and POs are the primary point of contact with patients, they offer expert knowledge on patients' behaviour and management of diseases. This plays a major role in informing Amgen's efforts to improve patient care and treatment options – which is essential to improving patient outcomes. We compensate HCPs, HCOs and POs for the valuable insights and time they offer, we also provide funding for medical education either directly to HCPs, via HCOs or third-party specialist providers.

Disclosing Transfers of Value (ToVs) such as payments and other benefits e.g., travel, and accommodation costs we make to HCPs, HCOs and POs will enhance the public understanding of why interactions are necessary to improve patient care. The pharmaceutical industry associations in each EFPIA country have introduced disclosure requirements into industry codes or countries have implemented laws on disclosure, Amgen will comply with the Codes or laws applicable in each country we operate conducting business with strong ethical principles and with the strictest integrity.

In line with the code or legal requirements, Amgen will publicly disclose the ToV it makes to HCPs, HCOs, and POs (hereafter 'Recipient').

In this document (hereafter 'Note') Amgen summarizes the methodologies used to prepare the disclosures and identify ToV.

## 2. SCOPE

This Note applies to the 36 countries<sup>1</sup> who are members of the **European Federation of Pharmaceutical Industries and Associations** (EFPIA) and Luxembourg where Amgen has interactions with Recipients.

Amgen discloses any support provided to Patient Organisations (e.g., donations, grants, payment for consulting services etc.) in accordance with the EFPIA Code of Practice. Latest disclosure reports can be found here [Link](#).

Support provided by the Amgen Foundation<sup>2</sup> can be found here [Link](#).

---

<sup>1</sup> Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, and the United Kingdom

<sup>2</sup> The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators and invest in strengthening communities where Amgen staff members live and work.

### 3. DEFINITIONS

[Link](#) to the **EFPIA Code of Practice** to learn more about the code, its definitions, and the general reporting requirements.

### 4. DATA COLLECTION FOR DISCLOSURE & IDENTIFICATION OF RECIPIENTS

#### 4.1. HOW AMGEN COLLECTS AND PROCESSES DATA

##### 4.1.1. DATA COLLECTION

Transfers of Value (ToV) to a Recipient in an EFPIA country can be provided by any Amgen entity across the world. Global and regional internal processes apply to interactions with such Recipients. These processes ensure interactions have a legitimate purpose and data is collected consistently, ensuring accuracy and capture of the required detail, regardless of the Amgen entity or the location of the interaction.

ToV can be provided:

- directly by Amgen to Recipients e.g., payments for services Recipients provided to Amgen, or
- indirectly by 3rd Parties e.g., accommodation, travel, or registration fees for HCPs to attend medical education events.

Contracts, with 3rd parties who provide any ToVs to Recipients on behalf of Amgen, mandate the collection of transparency related ToVs with the required accuracy and detail; Amgen maintains oversight of outsourced activities and responsibility for disclosure reporting. In principle, meals and drinks do not fall within the scope of the transparency obligations (exceptions may exist) and should not be disclosed, but when they are an integral or inseparable part of the ToV (e.g., included in the registration fee, hotel room rate) they will not be filtered out.

*Note: National laws and codes may have additional disclosure reporting requirements or deviate from the core requirements, Amgen is committed to meeting all requirements.*

For ToVs to HCPs and HCOs, transactions collected from different Amgen entities will be reviewed by the Amgen subsidiary / legal entity responsible for the disclosure. If Amgen has no legal entity in a particular EFPIA country, the Amgen entity with oversight of that country will conduct the data review and disclosure activities. For ToVs to POs, all transactions are reviewed by the Amgen entity making the ToV. Refer to the 'REPORTING' section for more information.

#### 4.1.2. DATE USED FOR DATA COLLECTION

Direct payments made by Amgen, generated through our financial system, will use the date the transaction was paid as the date of collection of the ToV. This approach is applicable to single and multi-year contracts which may result in multiple ToV.

In case of indirect payments (e.g., conferences where accommodation and/or travel is booked, or registration fees are paid on behalf of Recipients) all relevant expenses are collected from our 3rd Party Suppliers and imported into the Amgen data collection system. Preferably the conference or meeting date is captured as the date of collection of the ToV, where this is not possible the payment date of the ToV is used.

Amgen will collect ToVs for services both provided and paid as of 1st January each year and will report within the first 6 months of the following year or earlier as required by specific countries. To meet reporting requirements Amgen will close data processing activities for ToV made in the previous year by the end of February. Any ToV processed after this date will be disclosed either by republishing the previous report or inclusion in the disclosure report of the following year.

#### 4.1.3. TAX

Amgen reports ToV as net, e.g., without value added tax or withholding tax – unless the Disclosure Code / Legal requirements of a country state differently or the collection of net values is not possible through Amgen financial systems.

#### 4.1.4. CURRENCY MANAGEMENT

Amgen collects ToVs in the original currency in which they were made. The national disclosure report shows ToV in the country's own currency. Exchange rates are based on the approved currency exchange rates used by Amgen's validated financial systems and procedures which are subject to external inspection by independent auditors.

#### 4.1.5. UNIQUE IDENTIFIERS

Unique Country Local Identifiers (numbers) are provided in those countries where the local code or law mandates, and where the applicable data privacy laws and regulations allow.

#### 4.1.6. IF PLANNED TRANSFER OF VALUE DOES NOT TAKE PLACE

Genuine last-minute cancellations of travel or accommodation made on behalf of Recipients may occur due to emergency situations. Expenditure associated with such cancellations or unrecoverable spend is not attributed to the named Recipient as no ToV took place.

### 4.2. IDENTIFICATION OF RECIPIENTS

#### 4.2.1. CLEARLY IDENTIFIABLE RECIPIENT AND COUNTRY

Amgen has internal processes to ensure all ToVs made to Recipients are collected and reconciled in Amgen data collection and review tools. Amgen utilises both an internal and a proprietary commercial database from which both name and preferential business address are taken for disclosure. If a Recipient cannot be found in the proprietary commercial database Amgen will capture the required information for disclosure in its own database. These processes allow us to identify the Recipient of the ToV and ensure disclosure in accordance with code (or legal) requirements.

#### 4.2.2. CROSS-BORDER PAYMENTS / TRANSFERS OF VALUE

Amgen operates globally, our entities across the world have interactions with Recipients in EFPIA countries. Through our internal processes and systems, we are able to reconcile ToVs made to Recipients from EFPIA countries provided by Amgen entities across the world. Amgen's data collection and review tool receives transactions from the various Amgen entities and reconciles them i) for HCPs and HCOs - based on the country where the Recipient conducts business and where they will be reported. Quality checks are performed by the Amgen reporting entity; and ii) for POs - based on the country where the Amgen entity making the ToV is located. Quality checks are performed by the Amgen entity where the PO is located.

#### 4.2.3. PAYMENTS / TRANSFERS OF VALUE MADE BY 3RD PARTIES ON BEHALF OF AMGEN

Where a third-party company represents or acts on behalf of Amgen, Amgen ensures that its respective obligations are fulfilled in a written contract outlining how its obligations under the Disclosure Codes will be fulfilled.

#### 4.2.4. EDUCATION OF HCPs THROUGH HCOs and POs

If Amgen provides ToVs for medical education of HCPs through a HCO or PO, we will disclose the ToVs against the HCO or PO. If Amgen selects the individual HCPs who benefit from the educational event conducted by the HCO or

PO, we will disclose individually under the name of each HCP if they have provided consent under the relevant data privacy law.

#### 4.2.5. UNIVERSITIES AND TEACHING INSTITUTIONS

ToVs will be disclosed under the university or teaching institution which is the Recipient of the ToV if Amgen support or involvement benefits an HCP/HCO.

#### 4.2.6. HEALTHCARE PROFESSIONALS WHO OPERATE THROUGH THEIR OWN OR THIRD-PARTY COMPANIES

Some HCPs create their own company or work through a company to provide advice and services to the pharmaceutical industry. Amgen will capture the name and address of the company and disclose the ToV against the company as an HCO as required by the Codes.

#### 4.2.7. CLINICAL RESEARCH ORGANISATIONS & ETHICS COMMITTEES

A Clinical Research Organisation (CRO) is an organisation that provides support to the pharmaceutical, biotechnology and medical device industries in the form of research services outsourced on a contract basis. CROs are not healthcare organisations (HCOs), however if Amgen makes ToV to HCPs/HCOs through CROs Amgen will disclose the indirect ToV in the relevant disclosure category.

An Ethics Committee is designated to approve, monitor, and review biomedical and behavioural research involving humans. Amgen will never make payments to HCPs individually via an Ethics Committee.

## 5. CATEGORIES OF DISCLOSURE

### 5.1. DONATIONS AND GRANTS

Amgen provides Transfer of Value (ToV) as Grants or Donations to Recipients (not for profit HCOs and Patient Organisations) to:

- support science, technology, medicine, healthcare, research, education, or the needs of patients/caregivers,
- educate the public/patients on disease states, medical conditions, science, or technology,
- further genuine philanthropic and charitable purposes that are consistent with Amgen's scientific and disease-state interests.

Such donations are formalised in contracts that describe the purpose of the donation and the related ToV. If a 'donation in kind' is provided to a Recipient e.g., Amgen staff time, a monetary value will be attributed to the 'in kind' donation for the purpose of disclosure.

Donations and grants, and humanitarian aid in the form of Amgen medicinal products will be disclosed under "Donations and Grants" in the HCP/ HCO disclosure reports.

Patient Organisation reports detailing ToVs provided are published centrally on Amgen's corporate website [www.amgen.com](http://www.amgen.com).

## 5.2. CONTRIBUTION TO COST OF EVENTS

Amgen provides ToVs to Recipients for educational support at medical/educational events or congress for:

- TRAVEL AND ACCOMMODATION

Including the cost of flights, trains, car hire, tolls, parking fees, taxis, and hotel accommodation, etc.

- REGISTRATION FEES

The cost of registration fees for a Recipient to attend a medical / educational event or congress.

## 5.3. SPONSORSHIP AGREEMENTS WITH RECIPIENTS / THIRD PARTIES APPOINTED BY RECIPIENTS TO MANAGE AN EVENT

Amgen provides ToVs when sponsoring a Recipients event or project. Where a third-party company is a conference or event organiser acting on behalf of a Recipient Amgen will make every effort to disclose ToVs against the beneficiary Recipient(s) even when the payment is made to the third-party company. Agreements are formalised in contracts that describe the purpose of the sponsorship, the benefits Amgen receive and the related ToVs. If the sponsorship includes registration fees, travel, and accommodation, these will be disclosed separately in the relevant categories in the name of the HCO/ PO, unless the recipient HCP is known to Amgen whereby, we will disclose against the individual if we have the necessary consent. Agreements generally relate to rental of booth space, advertisement space, drinks and meals provided by the event organizer and satellite symposia at a medical / scientific congress. Where an event is organized by multiple HCOs/ POs cost will be apportioned accordingly.

## 5.4. FEE FOR SERVICE AND CONSULTANCY

Amgen provides ToVs for services Amgen receives from Recipients under service agreements. Services generally relate to advice on Amgen pipeline or marketed products, speaker fees, speaker training, data analysis, development of educational materials, retrospective non- interventional clinical studies or consulting / advising on future Amgen programs or projects. These will be disclosed in the relevant HCP/HCO and PO reports. Cost of travel and hotel

accommodation associated with services Amgen receive will be disclosed under "Service-Related Expenses" in the HCP/HCO disclosure reports.

#### 5.5. RESEARCH AND DEVELOPMENT TRANSFERS OF VALUE

Amgen is an innovative company with compounds in early research and products in development undergoing clinical trials. We provide ToVs to HCPs or HCOs related to the planning or conduct of non-clinical studies (e.g., laboratory), clinical trials and non-interventional studies<sup>3</sup>.

Non-Interventional Studies are designed to answer specific questions about a new drug treatment when prescribed by an HCP to a patient.

Research and Development ToVs in each reporting period are disclosed on an aggregated basis (without reference to names or addresses of Recipients). Costs related to events that are considered essential to effective study conduct e.g., Investigator Meetings, Steering Committee Meetings, Data Monitoring Committees are included in the aggregate amount in the "Research and Development Transfer of Value" category.

Amgen will not publish any information what would be seen as commercially sensitive, in compliance with relevant laws and regulations.

### 6. DATA PRIVACY / PROTECTION: HCPS (AND HCOS AS REQUIRED)

#### 6.1. MEETING DATA PRIVACY REQUIREMENTS

Data privacy laws exist to protect the personal information of individuals, these laws apply to HCPs in all countries and HCOs e.g., Austria and Luxembourg. To ensure Amgen comply with data privacy laws we require HCPs (and where relevant HCOs) consent to Amgen collecting, processing, and publishing summary details of the Transfers of Value (ToVs) we make during our interactions. If disclosures are required under local law consent will not be required.

Amgen has internal processes to ensure personal information is secure and protected in accordance with all applicable laws.

#### 6.2. CONSENT PROCESS

Amgen will obtain the consent, as required, of each HCP (or HCO where required by local privacy laws) to disclose their personal data primarily via data protection, privacy, and disclosure clauses in a contract, via a separate consent statement or via a consent statement in an invitation letter supported by a signing in roster of attendees to the event.



### 6.3. AGGREGATE DISCLOSURE

Where consent is required, HCPs (and where relevant HCOs) can withdraw their consent for the individual disclosure of their information at any time. Where their consent is withdrawn or not provided, Amgen will disclose all ToV made to them on an aggregate basis that does not identify them.

If an HCP (or HCO, where applicable) gives only partial consent to any aspect of disclosure, all ToVs Amgen made to that HCP (or HCO where applicable) will be disclosed in the aggregate category for the entire reporting period (calendar year), subject to applicable laws.

Partial disclosure under the individual category would be misleading with respect to the nature and scale of the interaction between Amgen and the HCP (HCO) and would not fulfil the intent of transparency through disclosure.

### 6.4. RECIPIENTS ACCESS TO THEIR DATA

In accordance with national privacy laws a Recipient, may request a copy of the information Amgen holds about them, including the information on ToVs which the company may publish against their name. A Recipient can request data they believe to be inaccurate be corrected. In such cases, Amgen will follow its internal processes to check and verify the identity of the Recipient and the accuracy of the data before making any necessary adjustments to its public disclosure reports.

To access their data, a Recipient can contact Amgen via the contact details mentioned in their contract with Amgen or by contacting our **Global Privacy Office** via e-mail: [privacy@amgen.com](mailto:privacy@amgen.com). Amgen will follow its internal processes to ensure all requests to access personal data are handled within the timelines specified by the relevant country data protection authorities.

## 7. REPORTING

### 7.1. QUALITY CHECKS PRIOR TO REPORTING

Prior to reporting, Amgen internal processes ensure Transfers of Value (ToVs) made to Recipients are collected and reconciled in Amgen data collection and review tools. Data quality checks are performed to ensure any Recipient who has not provided consent for individual disclosure are reported in 'aggregate', additional data and process monitoring takes place for quality assurance prior to reporting.

All ToVs to an HCP / HCO will be reported in the country where they conduct their main business irrespective of where the interaction occurred. All ToVs to POs will be reported under the Amgen affiliate making the ToV.

## 7.2. LOCATION OF DISCLOSURE REPORTS

### 7.2.1. PLATFORMS

Unless an EFPIA approved exception applies Amgen discloses ToVs in two ways depending on the Code or legal requirements of each country:

- on Amgen external webpages and/or
- via central platforms implemented by local industry associations or regulatory bodies in a specific country.

Amgen external webpages are the locations of the disclosure reports in the following countries: Austria, Bulgaria, Croatia, Finland, Germany, Greece, Hungary, Italy, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Switzerland, and the Netherlands.

Amgen's corporate external website [www.amgen.com](http://www.amgen.com) will be utilised for disclosures where Amgen does not have a legal entity, like Bosnia-Herzegovina, Cyprus, Estonia, Iceland, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Serbia, and Ukraine. Amgen will also disclose ToVs to Recipients in Luxembourg and to POs on this corporate site.

Amgen publishes ToVs made to recipient HCPs and HCOs on central platforms in following countries: Belgium, Czech Republic, France, Ireland, Portugal, Romania, Slovakia, Sweden, the Netherlands, and UK.

In the event that Amgen has more than one business in a single country ToV are disclosed on a single Amgen webpage in that country (or on the same central platform) for ease of access.

### 7.2.2. LANGUAGE OF DISCLOSURE REPORTS

Amgen will make reports available in the languages required by each local code or law.

## 8. COUNTRY NATIONAL DISCLOSURE CODE / LAW

### CONSENT PROCESS CHANGES

As of 1st July 2022, Amgen has transitioned to Legitimate Interests as the legal basis for processing personal transfer of value data in the interests of transparency. As such, Amgen is not required to obtain consent from each HCP. The aim is to help increase the number of named disclosures of transfer of value to healthcare professionals.

### ABPI CODE, CLAUSE 1.8 SUPPLEMENTARY INFORMATION

If an HCO consists of only one HCP or other relevant decision maker (ORDM), or the HCP/ORDM is the majority shareholder, then it would be subject to the requirements in the Code regarding individual HCPs.

#### COLLABORATIVE WORKING EXECUTIVE SUMMARIES

Collaborative working refers to the partnerships formed between pharmaceutical companies and other organisations to deliver initiatives that enhance patient care, are for the benefit of patients, or alternatively benefits the NHS and, as a minimum, maintains patient care. Joint working is a subtype of company collaboration that is specifically patient-centred and designed to always benefit patients. Please refer to the [Amgen UK website](#).

#### MEMBER OF THE PUBLIC INCLUDING PATIENTS

The 2021 ABPI Code brought in a new disclosure requirement for Companies to make publicly available annually aggregate details of the fees for certain contracted services paid to members of the UK public including patients and journalists (MoP). These services include speaking at meetings, assistance with training, writing articles and/or publications, participating in advisory boards, advising on the design etc of clinical trials, participating in market research where such participation involves remuneration and/or travel. MoP information is published on companies' own websites annually, starting with 2022 data.

## 9. RELATED REFERENCE DOCUMENTS

EFPIA for the National Member Associations' Codes of Practice on the promotion of prescription- only medicines to, and interactions with, healthcare professionals and healthcare organizations: [Link](#).

## 10. DOCUMENT HISTORY

Version	Summary of Change	Description of the Chage
4.0	No content change in the document. The document type changed from "Internal Use Only" to "Public".	The document tpye changed from "Internal Use Only" to "Public".
3.0	Section 8.0 "EXCEPTIONAL HANDLING OF TOV DUE TO THE PANDEMIC" renamed to "COUNTRY NATIONAL DISCLOSURE CODE / LAW"	Removed "Exceptional Handling of ToV Due to The Pandemic" and renamed to allow capturing specific country requirements.
2.0	Section 8.0 Exceptional Handling of ToV Due to The Pandemic added	New section added which included details of Amgen business activities that were impacted by COVID-19.
1.0	Amgen's Methodological Note	Initial document